A Phase 1b/2 Study of AMP945 in Pancreatic Cancer

Study Description

A Study to Evaluate the Effectiveness of AMP945 in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Cancer

Study Details

Registry ID:

NCT05355298

Conditions:

Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma

Phase:

Phase 1,Phase 2

Target Enrollment:

62 participants

Start Date:

May 31, 2022

Healthy Volunteers:

No

Study Locations (13 sites)

• National Cancer Centre
  Gyeonggi-doKorea, Republic of, Korea, Republic of
• Seoul National University Bundang Hospital
  Gyeonggi-doKorea, Republic of, Korea, Republic of
• Severence Hospital
  SeoulKorea, Republic of, Korea, Republic of
• Seoul National University Hospital
  SeoulKorea, Republic of, Korea, Republic of
• Samsung Medical Centre
  SeoulKorea, Republic of, Korea, Republic of
• Western Health
  St Albans, VictoriaAustralia, Australia
• Epworth Healthcare
  Richmond, VictoriaAustralia, Australia
• Epworth Healthcare
  Box Hill, VictoriaAustralia, Australia
• Monash Health
  Clayton, VictoriaAustralia, Australia
• Westmead Hospital
  Westmead, New South WalesAustralia, Australia
• GenesisCare
  St Leonards, New South WalesAustralia, Australia
• Calvary Mater Newcastle
  Waratah, New South WalesAustralia, Australia
• Gallipolli Medical Research Foundation
  Greenslopes, QueenslandAustralia, Australia

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →